Instead, associations of mutations in the polymorphic region (5-HTTLPR) of SLC6A4 and IBS-C were observed only in the East Asian population to suggest that assessment of genetic variations may be more useful for pharmacogenomics and in predicting responses to drug therapies153 than as biomarkers for IBS. This evidence concerns the gene SLC6A4 and irritable bowel syndrome.